Viora V30
IPL multi-app platform · V-IPL + diode + RF modular
Technology: Diode Laser
Classification & configurations
Category group: Hair removal (diode, alexandrite, Nd:YAG, IPL)
At a glance
- New price
- $50k–$80kSource not documented
- Used asking price
- $20k–$35kSource not documented
- FDA status
- Supplies & recurring costs
- Supply details not yet documented.
Sources and verified data on file
Data on file
- Recurring consumables
- Not verified
- FDA
- FDA ClearedK133837
- Used asking prices
- Not verified
- This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
- Bottle prices and estimates may still appear under Treatment & running costs.
- The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.
Figures are reference points, not current offers. Used asking prices are not completed-sale values.
Read FDA-cleared indicationsExact wording from 1 FDA record
K133837 (Viora, Ltd., 2014)
The Viora V-total 7"' isintended for dermatological procedures. The ST handpiece is indicated for the treatment of relief of minor muscle aches and pain, relief of muscle spasm and temporary improvement of local blood circulation. The IPL handpiece with wavelengths 415-l200nm (with 5 different filters) is indicated for the treatment of:. * Moderate inflammatory acne vulgaris. * Benign pigmented epidermal lesions including dyschromia, hyperpigmentation, melasrna, and ephelides (freckles). * Cutaneous lesions including warts, scars and striae. "Benign cutaneous vascular lesions including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacca, erythema of rosacca, angiomnas and spider angiomnas, poikiloderma of Civatte and venous malformations. * Removal unwanted hair. It is also intended for permanent reduction in unwanted hair. Permanent hair reduction is defined as the long-term stable reduction inthe number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regimen. The Nd:YAG Laser handpiece with wavelength 1064 nm comes with 4 different applicator spot diameters: 2x4, 3.5, 5.5 and 9.5 mm. The three smaller spot sizes (2x4, 3.5, 5.5 mm) are intended for: - Benign vascular lesions such as, but not limited to treatment of: port wine stains, hemangiomas, Warts, superficial and deep telangiectasias (venulectasias). reticular veins (0. 1-4.0mmn dia.) of the leg, rosace, venus lake, leg veins, spider veins, poikiloderma of civatte and angiomas. * Benign cutaneous lesions, such as, but not limited to: warts, scars, striae and psoriasis. * Benign pigmented lesions such as, but not limited to: lentigos (age spots), solar lentigos (sun spots), cafe-aulait macules, seborrheic keratosis, nevi and nevus of One, chloasma, verrucae, skin tags and keratosis. - Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. ' The non-ablative treatment of facial wrinkles, such as, but not limited to: periocular wrinkles and perioral wrinkles. "The handpiece with a spot size of 9.5 mm is also intended for treatment of: Laser skin resurfacing procedures for the treatment of: acne scars and wrinkles. Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral pant of the scar.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Page updated: September 7, 2026 · How we verify
Axis runs $0–$80k. Reference figures, not current offers. Used asking prices are not completed-sale values.
Not verified
We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.
Price sourcesSources, dates and configurations
Key factsCompany, specifications and verification dates
| Manufacturer | Viora |
|---|---|
| Company | Owner: Sinclair Pharma, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (subsidiary, since 2022) |
| Parent company | Sinclair Pharma (Huadong Medicine) |
| Brand owner | Viora |
| Built by (OEM) | Viora Ltd. |
| Category | IPL multi-app platform |
| Technology | V-IPL + diode + RF modular |
| FDA status | FDA Cleared |
| 510(k) citation | K133837 |
| New price range | $50k–$80k |
| Used asking range | $20k–$35k |
| Consumables | Not published |
| Launch year | 2018 |
| Pricing | Not published |
| Manufacturer-source documents checked | Not published |
Overview
Modular multi-app with PCR IPL
FDA & regulatory detailClearance timeline, authorization route and citation notes
Family clearance: K133837 names V-TOTAL. Checked 4 Sep 2026.
FDA-cleared indications (verbatim)
K133837 (Viora, Ltd., 2014)
The Viora V-total 7"' isintended for dermatological procedures. The ST handpiece is indicated for the treatment of relief of minor muscle aches and pain, relief of muscle spasm and temporary improvement of local blood circulation. The IPL handpiece with wavelengths 415-l200nm (with 5 different filters) is indicated for the treatment of:. * Moderate inflammatory acne vulgaris. * Benign pigmented epidermal lesions including dyschromia, hyperpigmentation, melasrna, and ephelides (freckles). * Cutaneous lesions including warts, scars and striae. "Benign cutaneous vascular lesions including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacca, erythema of rosacca, angiomnas and spider angiomnas, poikiloderma of Civatte and venous malformations. * Removal unwanted hair. It is also intended for permanent reduction in unwanted hair. Permanent hair reduction is defined as the long-term stable reduction inthe number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regimen. The Nd:YAG Laser handpiece with wavelength 1064 nm comes with 4 different applicator spot diameters: 2x4, 3.5, 5.5 and 9.5 mm. The three smaller spot sizes (2x4, 3.5, 5.5 mm) are intended for: - Benign vascular lesions such as, but not limited to treatment of: port wine stains, hemangiomas, Warts, superficial and deep telangiectasias (venulectasias). reticular veins (0. 1-4.0mmn dia.) of the leg, rosace, venus lake, leg veins, spider veins, poikiloderma of civatte and angiomas. * Benign cutaneous lesions, such as, but not limited to: warts, scars, striae and psoriasis. * Benign pigmented lesions such as, but not limited to: lentigos (age spots), solar lentigos (sun spots), cafe-aulait macules, seborrheic keratosis, nevi and nevus of One, chloasma, verrucae, skin tags and keratosis. - Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. ' The non-ablative treatment of facial wrinkles, such as, but not limited to: periocular wrinkles and perioral wrinkles. "The handpiece with a spot size of 9.5 mm is also intended for treatment of: Laser skin resurfacing procedures for the treatment of: acne scars and wrinkles. Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral pant of the scar.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Marketed for
Diode laser — V-IPL + diode + RF modular
Marketing claims are the manufacturer's own and are not the same as a cleared indication.
Parent company: Sinclair Pharma (Huadong Medicine)
Legal manufacturer: Viora Ltd. (Israel)
Applicant on the FDA record
Viora Ltd.The applicant named on the FDA record can differ from the brand shown on the device.
Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.
Treatment & running costs
Treatments
Sessions & timing
No treatment schedule documented yet.
What practices charge
No sourced treatment price on file.
Supplies & recurring costs
Consumable costs are not documented yet.
Annual service & support
No annual service cost documented yet.
Payback calculatorModel your own volume, labor and service costs
Estimate your payback
Pre-filled from our published Viora V30 data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.
Start from
No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.
Pre-filled from the midpoint of the published new-price range
20 is an illustrative default — change it to your volume.
No sourced per-session price on file — enter what you charge.
Required — enter your cost; missing data does not mean $0.
Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.
Annual service contract ÷ 12, if you carry one.
Your estimate
Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.
This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.
Warranty & serviceWhat to confirm in writing before you buy
Before buying new or used, confirm in writing:
- Current warranty coverage
- Included training
- Service terms
Chains using this device
A chain listing does not establish availability at every location.
No confirmed chain deployments recorded yet.
Owner & operator reviews
Write a reviewNo owner or operator reviews yet. Be the first →
Current alternatives
Current catalog models to research. Confirm availability and configuration with the supplier.
History7 tracked changes
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
September 7, 2026
parent company
Viora → Sinclair Pharma (Huadong Medicine)
Ultimate owner updated against a dated primary source (8 Sep 2026).
Source: https://sinclair.com/news/sinclair-announces-acquisition-of-viora/
September 4, 2026
FDA status
Unknown → Cleared
Clearance located on openFDA
Source: Council round 2 audit, verified on openFDA 2026-09-04
September 4, 2026
FDA status
Unknown → Cleared
Source: Catalog update
September 4, 2026
FDA source URL
Source: Catalog update
September 4, 2026
510(k) numbers
K-number set re-verified against openFDA
Source: Council round 2 audit, verified on openFDA 2026-09-04
September 4, 2026
FDA K-numbers
Source: Catalog update
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Cite this data: The Aesthetic Index, "Viora V30 — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).
Get the full State of Aesthetic Devices 2026 report
A catalog of US-marketed aesthetic and wellness devices — preview it free.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.